The mhGAP guideline has been developed to help countries improve their ability to address the increasing challenges of mental, neurological and substance use (MNS) conditions and reduce the treatment gap. With 30 updated and 18 new recommendations, along with 90 existing recommendations, this latest edition is the third iteration of the guideline and reflects years of investment in the mhGAP programme. These revised recommendations are designed to ensure that mhGAP provides non-specialist health workers in low and middle-income countries with high-quality, timely, transparent, and evidence-based guidance to effectively treat and care for individuals with MNS conditions.
The need for improved capacity to address MNS conditions is growing, and the mhGAP guideline aims to assist countries in meeting this challenge. With a focus on narrowing the treatment gap, the latest edition of the guideline includes 30 updated recommendations and 18 new recommendations, in addition to the 90 pre-existing recommendations. This represents the third iteration of the guideline and is the result of significant investment in the mhGAP programme over the past 15 years. The revised recommendations are intended to ensure that mhGAP continues to provide high-quality, timely, transparent, and evidence-based guidance to support non-specialist health workers in low and middle-income countries in delivering treatment and care for individuals with MNS conditions.